ArticleExperimental and therapeutic medicine2026
Baseline neutrophil-to-lymphocyte ratio is not associated with chemotherapy-induced nausea and vomiting in patients with breast cancer: A single-center retrospective cohort study.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of highly emetogenic chemotherapy despite advances in antiemetic prophylaxis. Systemic inflammatory markers have previously been investigated as potential predictors of treatment-associated toxicities in oncology. The present study aimed to evaluate the association between baseline neutrophil-to-lymphocyte ratio (NLR) and the risk of CINV in patients with breast cancer receiving anthracycline-based chemotherapy. The present retrospective cohort included 280 female patients with histologically determined breast cancer who received anthracycline and cyclophosphamide chemotherapy at a single tertiary oncology center. Baseline neutrophil and lymphocyte counts obtained prior to chemotherapy initiation were used to calculate the NLR. Patients were categorized into two groups according to NLR values: Low NLR (<3) and high NLR (≥3). The primary endpoint was complete response (CR), defined as the absence of vomiting and no need for rescue antiemetic therapy. CR rates were evaluated in the acute (0-24 h), delayed (24-120 h) and overall (0-120 h) phases following chemotherapy. Associations between NLR and clinical outcomes were assessed using χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.